AbbVie, on a Mission, picks Alzheimer's, Parkinson's targets, as partner nabs $20M

AbbVie has advanced a collaboration with Mission Therapeutics after getting a look at data from preclinical models of Alzheimer’s and Parkinson’s diseases, teeing up a $20 million milestone payment.